Amy Connolly, PA
Physician Assistant · Southfield, MINPI 1033106331
Payments from drug & device makers
Across 144 payments — averaging $15.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$416
- GSK$382
- Novo Nordisk$226
- AstraZeneca$185
- Sanofi-aventis U.S. LLC$149
- Lilly USA, LLC$128
- plus $780 from 15 others
What the payments were for
- Food & beverage$2,266100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 26 | $416 |
| GSK | 19 | $382 |
| Novo Nordisk | 23 | $226 |
| AstraZeneca | 13 | $185 |
| Sanofi-aventis U.S. LLC | 9 | $149 |
| Lilly USA, LLC | 8 | $128 |
| Pfizer | 6 | $101 |
| Novartis | 6 | $88 |
| Teva Pharmaceuticals USA, Inc. | 5 | $88 |
| Amgen | 5 | $76 |
| Bayer | 4 | $67 |
| Boehringer Ingelheim | 4 | $61 |
| Xeris Pharmaceuticals, Inc. | 3 | $53 |
| Nestle Healthcare Nutrition Inc. | 2 | $49 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Dexcom, Inc. | 2 | $36 |
| Lundbeck LLC | 2 | $34 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $33 |
| Exact Sciences | 1 | $23 |
| Indivior Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AREXVY$107
How this compares
$2,266 in reported general payments places this provider in the 85th percentile of 5,453 physician assistant providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 128 | $93,777 |
| RybelsusSemaglutide | 64 | $83,742 |
| OzempicSemaglutide | 67 | $74,607 |
| Tresiba Flextouch U-200Insulin Degludec | 87 | $70,175 |
| JanuviaSitagliptin Phosphate | 73 | $68,583 |
| EliquisApixaban | 64 | $51,968 |
| XareltoRivaroxaban | 53 | $45,768 |
| JardianceEmpagliflozin | 45 | $42,614 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 18 | $34,448 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 58 | $30,693 |
| Breo ElliptaFluticasone/Vilanterol | 52 | $26,457 |
| TradjentaLinagliptin | 37 | $25,249 |
| EntrestoSacubitril/Valsartan | 18 | $24,815 |
| TrulicityDulaglutide | 24 | $22,718 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $22,715 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic, Xultophy 100-3.6 | $226 | $192,796149 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $382 | $150,927238 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Jentadueto | $61 | $80,338106 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort, Brilinta | $185 | $66,368123 claims |
| PfizerEliquis, Nurtec Odt | $101 | $64,01576 claims |
| NovartisEntresto | $88 | $24,81518 claims |
| Lilly USA, LLCTrulicity | $128 | $22,71824 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $36 | $19,71514 claims |
| BayerKerendia | $67 | $17,39118 claims |
| Astellas Pharma US IncMyrbetriq | $17 | $9,01915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,453 physician assistant providers in Michigan.
Other physician assistant in Southfield
- Sarang PatelRoyal Oak$660K
- Beth SweneyAda$617K
- Zainab JishiCanton$596K
- Taylor HennrickAdrian$430K
- Erin van DykeGrand Rapids$346K
- Ashley AldridgeAnn Arbor$298K
- Derek SusallaRochester Hills$242K
- Gabrielle DamoreRoyal Oak$200K
- Melissa MickelsonKalamazoo$168K
- Patrick CooneyNew Baltimore$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.